Movement Alert｜Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Pharmaceutical Sector Recovery Coupled with Multiple Pipeline Catalysts

Market Focus07-20

On July 20, Hansoh Pharmaceutical rose 3.08% in regular trading, trading at HK$32.62/share, with turnover of approximately HK$81.25 million. The broader pharmaceutical sector strengthened in tandem, with multiple heavyweight names posting gains.

The rally comes amid a confluence of recent catalysts. On July 14, Hansoh announced that its invested company Avere Therapeutics signed a merger agreement with Nasdaq-listed NextCure, through which Hansoh's oral IL-23 receptor antagonist HS-20118 gained a global exclusive license pathway with up to US$1.2 billion in upfront payments and US$2.18 billion in milestone payments. Hansoh is expected to hold 30%-40% of the merged entity. Additionally, on July 10, the company reported that its B7-H3-targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer, marking it as the first B7-H3 ADC globally to demonstrate OS benefit in a Phase III study.

Within the Pharmaceuticals sector, CSPC Pharma rose 3.46%, Asymchem gained 2.9%, Hengrui Pharma advanced 2.91%, Sunshine Pharma climbed 5.64%, and SBP Group added 2.41%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191934234?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191934234","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Pharmaceutical Sector Recovery Coupled with Multiple Pipeline Catalysts","media":"Market Focus","content":"<p><p>On July 20, Hansoh Pharmaceutical rose 3.08% in regular trading, trading at HK$32.62/share, with turnover of approximately HK$81.25 million. The broader pharmaceutical sector strengthened in tandem, with multiple heavyweight names posting gains.</p><p>The rally comes amid a confluence of recent catalysts. On July 14, Hansoh announced that its invested company Avere Therapeutics signed a merger agreement with Nasdaq-listed NextCure, through which Hansoh's oral IL-23 receptor antagonist HS-20118 gained a global exclusive license pathway with up to US$1.2 billion in upfront payments and US$2.18 billion in milestone payments. Hansoh is expected to hold 30%-40% of the merged entity. Additionally, on July 10, the company reported that its B7-H3-targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer, marking it as the first B7-H3 ADC globally to demonstrate OS benefit in a Phase III study.</p><p>Within the Pharmaceuticals sector, CSPC Pharma rose 3.46%, Asymchem gained 2.9%, Hengrui Pharma advanced 2.91%, Sunshine Pharma climbed 5.64%, and SBP Group added 2.41%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Pharmaceutical Sector Recovery Coupled with Multiple Pipeline Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Pharmaceutical Sector Recovery Coupled with Multiple Pipeline Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, Hansoh Pharmaceutical rose 3.08% in regular trading, trading at HK$32.62/share, with turnover of approximately HK$81.25 million. The broader pharmaceutical sector strengthened in tandem, with multiple heavyweight names posting gains.</p><p>The rally comes amid a confluence of recent catalysts. On July 14, Hansoh announced that its invested company Avere Therapeutics signed a merger agreement with Nasdaq-listed NextCure, through which Hansoh's oral IL-23 receptor antagonist HS-20118 gained a global exclusive license pathway with up to US$1.2 billion in upfront payments and US$2.18 billion in milestone payments. Hansoh is expected to hold 30%-40% of the merged entity. Additionally, on July 10, the company reported that its B7-H3-targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer, marking it as the first B7-H3 ADC globally to demonstrate OS benefit in a Phase III study.</p><p>Within the Pharmaceuticals sector, CSPC Pharma rose 3.46%, Asymchem gained 2.9%, Hengrui Pharma advanced 2.91%, Sunshine Pharma climbed 5.64%, and SBP Group added 2.41%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1191934234","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191934234","pubTimestamp":1784512845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, Hansoh Pharmaceutical rose 3.08% in regular trading, trading at HK$32.62/share, with turnover of approximately HK$81.25 million. The broader pharmaceutical sector strengthened in tandem,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势提醒|豪森制药常规交易上涨3.08%，医药板块复苏叠加多重管道催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 20, Hansoh Pharmaceutical rose 3.08% in regular trading, trading at HK$32.62/share, with turnover of approximately HK$81.25 million. The broader pharmaceutical sector strengthened in tandem, with multiple heavyweight names posting gains.The rally comes amid a confluence of recent catalysts. On July 14, Hansoh announced that its invested company Avere Therapeutics signed a merger agreement with Nasdaq-listed NextCure, through which Hansoh's oral IL-23 receptor antagonist HS-20118 gained a global exclusive license pathway with up to US$1.2 billion in upfront payments and US$2.18 billion in milestone payments. Hansoh is expected to hold 30%-40% of the merged entity. Additionally, on July 10, the company reported that its B7-H3-targeted ADC HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer, marking it as the first B7-H3 ADC globally to demonstrate OS benefit in a Phase III study.Within the Pharmaceuticals sector, CSPC Pharma rose 3.46%, Asymchem gained 2.9%, Hengrui Pharma advanced 2.91%, Sunshine Pharma climbed 5.64%, and SBP Group added 2.41%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191934234","isCrawlerRequest":true}